ARF6 and lung adenocarcinoma: Clinically, ARF6 expression and activation of its downstream signaling pathways was determined and associated with poor overall survival of breast, lung adenocarcinoma, pancreatic ductal adenocarcinoma and head and neck cancer patients (Li R. et al., 2017).